Page last updated: 2024-11-12
eponemycin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
eponemycin: structure given in first source; isolated from Streptomyces hygroscpicus No. P247-71; active against B16 melanoma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10092280 |
| SCHEMBL ID | 13523606 |
| MeSH ID | M0174743 |
Synonyms (7)
| Synonym |
|---|
| eponemycin |
| heptanamide, n-(1-(hydroxymethyl)-2-((1-((2-(hydroxymethyl)oxiranyl)carbonyl)-3-methyl-3-butenyl)amino)-2-oxoethyl)-6-methyl- |
| antibiotic bu 3862t |
| 126509-46-4 |
| 1,2-epoxy-2-hydroxymethyl-4-(n-isooctanoylserylamino)-6-methylhept-6-ene-3-one |
| SCHEMBL13523606 |
| n-[(2s)-3-hydroxy-1-[[(2s)-1-[(2r)-2-(hydroxymethyl)oxiran-2-yl]-4-methyl-1-oxopent-4-en-2-yl]amino]-1-oxopropan-2-yl]-6-methylheptanamide |
Research Excerpts
Overview
Eponemycin is an α,β-epoxyketone natural product that inhibits the proteasome.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Eponemycin is an α,β-epoxyketone natural product that inhibits the proteasome " | ( Chemoenzymatic Synthesis of Novel Cytotoxic Epoxyketones Using the Eponemycin Biosynthetic Enzyme EpnF. Corless, BC; David, Y; Geißen, R; Prescott, NA; Scheinberg, DA; Tan, DS, 2023) | 2.59 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.80
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.80) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||